Skip to main content

DESACAND HCT, DESARTACAN HCT, CANDESARTAN HCTZ GPPL, TACCASART HCT, CANDESARTAN BUR HCT, TACETAN HCT, XILECAND HCT, XILENTO HCT (Generic Partners Pty Ltd)

Product name
DESACAND HCT, DESARTACAN HCT, CANDESARTAN HCTZ GPPL, TACCASART HCT, CANDESARTAN BUR HCT, TACETAN HCT, XILECAND HCT, XILENTO HCT
Date registered
Evaluation commenced
Decision date
Approval time
251 working days (255)
Active ingredients
candesartan cilexetil and hydrochlorothiazide
Registration type
New generic medicine
Indication

DESACAND HCT, DESARTACAN HCT, CANDESARTAN HCTZ GPPL, TACCASART HCT, CANDESARTAN BUR HCT, TACETAN HCT, XILECAND HCT, XILENTO HCT (tablets) are indicated for the treatment of hypertension. Treatment should not be initiated with these fixed dose combinations.

Help us improve the Therapeutic Goods Administration site